共 37 条
- [21] BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGSLeukemia, 2021, 35 : 2102 - 2107Simona SoveriniMargherita MartelliLuana BavaroCaterina De BenedittisSimona SicaFederica SoràAlessandra IurloMassimiliano BonifacioPatrizia PregnoSara GalimbertiFrancesca LunghiFrancesco AlbanoMariella D’AddaMonica CrugnolaIsabella CapodannoFausto CastagnettiGabriele GugliottaCristina PapayannidisGianantonio RostiAntonio PercesepeFlavio MignoneMichele BaccaraniGiovanni MartinelliMichele Cavo
- [22] AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCANCER CELL, 2009, 16 (05) : 401 - 412O'Hare, ThomasShakespeare, William C.Zhu, XiaotianEide, Christopher A.Rivera, Victor M.Wang, FrankAdrian, Lauren T.Zhou, TianjunHuang, Wei-ShengXu, QihongMetcalf, Chester A., IIITyner, Jeffrey W.Loriaux, Marc M.Corbin, Amie S.Wardwell, ScottNing, YaoyuKeats, Jeffrey A.Wang, YihanSundaramoorthi, RajiThomas, MathewZhou, DongSnodgrass, JosephCommodore, LoisSawyer, Tomi K.Dalgarno, David C.Deininger, Michael W. N.Druker, Brian J.Clackson, Tim
- [23] A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialBLOOD, 2012, 120 (21)Cortes, Jorge E.Kim, Dong-WookPinilla-Ibarz, Javierle Coutre, PhilippPaquette, RonChuah, CharlesNicolini, Franck E.Apperley, JaneKhoury, H. JeanTalpaz, MosheDiPersio, John F.DeAngelo, Daniel J.Abruzzese, ElisabettaRea, DelphineBaccarani, MicheleMuller, Martin C.Gambacorti-Passerini, CarloWong, StephaneLustgarten, StephanieRivera, Victor M.Clarkson, TimTurner, Christopher D.Haluska, Frank G.Guilhot, FrancoisDeininger, Michael W.Hochhaus, AndreasHughes, TimothyGoldman, John M.Shah, NeilKantarjian, Hagop M.
- [24] KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph plus Leukemia Including BCR-ABL/T315I Both in Vitro and in VivoBLOOD, 2008, 112 (11) : 579 - 579Shiotsu, YukimasaKiyoi, HitoshiTanizaki, RyoheiMinami, YosukeAbe, AkihiroIshikawa, YuichiIshii, KenichiShimizu, MakikoKanda, YutakaSato, YukoAkinaga, ShiroCortes, JorgeNaoe, Tomoki
- [25] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).BLOOD, 2001, 98 (11) : 260B - 260BKantarjian, HMCortes, JO'Brien, SGiles, FAlbitar, MRios, MBShan, JFaderl, SGarcia-Manero, GIssa, JPThomas, DCapdeville, RTalpaz, M
- [26] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) or Have the T315I MutationCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S271 - S272Gore, LiaLoh, MignonPui, Ching-HonHanley, Michael J.Du, JichangMatloub, YousifHennessy, MeliessaGranier, MurielBiondi, AndreaSilverman, Lewis
- [27] Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Kantarjian, Hagop M.Kim, Dong-WookPinilla-Ibaz, JavierLe Coutre, Philipp D.Paquette, RonaldChuah, CharlesNicolini, Franck E.Apperley, JaneKhoury, Hanna JeanTalpaz, MosheDiPersio, John F.Baccarani, MicheleLustgarten, StephanieHaluska, Frank G.Guilhot, FrancoisDeininger, Michael W. N.Hochhaus, AndreasHughes, Timothy P.Shah, Neil P.Cortes, Jorge E.
- [28] Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation SequencingBLOOD, 2018, 132Soverini, SimonaBavaro, LuanaMartelli, MargheritaDe Benedittis, CaterinaIurlo, AlessandraOrofino, NicolaPagano, LivioCriscuolo, MariannaBonifacio, MassimilianoScaffidi, LuigiSica, SimonaSora, FedericaMaino, ElenaRondoni, MichelaLaginestra, Maria AntonellaLunghi, FrancescaErmacora, AnnaD'adda, MariellaGugliotta, GabrieleCastagnetti, FaustoRosti, GianantonioPapayannidis, CristinaMarconi, GiovanniCurti, AntonioMiggiano, Maria CristinaGalimberti, SaraPercesepe, AntonioStagno, FabioSancetta, RosariaAnnunziata, MarioFalzetti, FrancaCapodanno, IsabellaPregno, PatriziaMaffioli, MargheritaIntermesoli, TamaraDi Bona, ErosCaocci, GiovanniAttolico, ImmaBinotto, GianniBocchia, MonicaAngelucci, EmanueleSgherza, NicolaLuciano, LuigianaMignone, FlavioPileri, Stefano A.Martinelli, GiovanniCavo, Michele
- [29] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBLOOD, 2007, 110 (10) : 3540 - 3546Kantarjian, Hagop M.Giles, FrancisGattermann, NorbertBhalla, KapilAlimena, GiulianaPalandri, FrancescaOssenkoppele, Gert J.Nicolini, Franck-EmmanuelO'Brien, Stephen G.Litzow, MarkBhatia, RaviCervantes, FranciscoHaque, ArifulShou, YapingResta, Debra J.Weitzman, AaronHochhaus, Andreasle Coutre, Philipp
- [30] MK-0457, a novel multikinase inhibitor, is active in patients with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) with the T315I BCR-ABL resistance mutation and patients with refractory JAK-2 positive myeloproliferative diseases (MPD)HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 347 - 347Giles, J.Cortes, J.Bergstrom, D. A.Xiao, A.Jones, D.Verstovsek, S.Thomas, D.Rizzieri, D.Freedman, S. J.Kantarjian, H.